LUNG CANCER

Up-to-date insights on disease, treatment, and care based on real-world data from Komodo’s full-stack healthcare analytics platform

Lung cancer is the third most common cancer in the U.S. and the leading cause of cancer-related mortality. While overall rates have declined in recent decades, largely due to a reduction in smoking, lung cancer still leads to more deaths than breast, prostate, and colon cancers combined. Older adults are most affected by lung cancer, but in recent years, research has shown increasing rates among younger age brackets.

PREVALENCE

Based on data available in Komodo’s Healthcare Map™, there were approximately 518,866 insured Americans living with lung cancer in 2022.

TIME TO TREATMENT

Days from Diagnosis to Treatment, by Age Group

- Under Age 35:
  - Chemotherapy: 50
  - Surgery: 18
- Age 35 and Above:
  - Chemotherapy: 60
  - Surgery: 33

Patients under age 35 received chemotherapy 10 days sooner and received surgery 15 days sooner than patients ages 35 and over, on average.

DEMOGRAPHICS

Based on data available in Komodo’s Healthcare Map of newly diagnosed lung cancer patients in 2022:

- Race and Ethnicity:
  - White: 76%
  - Black: 11%
  - Hispanic or Latino: 7%
  - Asian or Pacific Islander: 3%
  - Other: 2%

- Age:
  - 56–88 Years Old: 91%
  - 35–55 Years Old: 8%
  - 18–34 Years Old: 1%

- Gender:
  - Male: 50%
  - Female: 50%
SMOKING STATUS *

Among patients diagnosed with lung cancer in 2022:
- 79% were smokers (52% were male, 48% female; 59% were between 65–88 years old)
- 21% were not smokers

Among current smokers who received a screening CT scan:
- 50% were male
- 50% were female
- 77% were White
- 12% were Black
- 99.8% were ages 45–88
- 2% received a lung cancer diagnosis within a year of their scan

Presentation and Patient Characteristics

**Comorbidities**
- 76% Hypertension
- 47% Chronic obstructive pulmonary disease
- 33% Type 2 diabetes
- 31% Anxiety

**Red Flag Symptoms**
- 55% Shortness of breath
- 41% Chest pain
- 33% Cough

**Nonspecific Symptoms**
- 31% Abdominal pain
- 20% Acute respiratory infection
- 20% Nausea
- 3% Fever

**Presentation and Patient Characteristics**

**Comorbidities**
- 35% Anxiety
- 24% Hypertension
- 9% Type 2 diabetes
- 5% Chronic obstructive pulmonary disease

**Top Diagnosing Specialties**
- Radiology, diagnostic
- Internal medicine
- Emergency medicine

**Presentation and Patient Characteristics**

**Comorbidities**
- 44% Hypertension
- 42% Fever
- 35% Acute respiratory infection
- 32% Nausea

**Top Diagnosing Specialties**
- Hematology and oncology
- Internal medicine
- Pulmonary disease

**Screening, Diagnosis, and Management**

**Most commonly performed diagnostic scan:**
- Chest X-ray
- CT scan
- MRI scan

**Most commonly used therapies/procedures:**
1. Intravenous pembrolizumab
2. Mid-chest lymph node removal
3. Lung lobe removal
4. Intravenous atezolizumab
5. Intravenous durvalumab

Percentage of patients age 35 or older with an emergency department visit prior to their lung cancer diagnosis: 33%

Percentage of patients under age 35 with an emergency department visit prior to their lung cancer diagnosis: 42%

*Determined using a variety of EMR sources covering a multitude of inpatient and outpatient disease settings, country-wide.

Komodo Health Fast Facts are derived from the Komodo Healthcare Map, the largest and most complete database of de-identified, real–world patient data. The Healthcare Map uses artificial intelligence and advanced analytics to track the individual encounters with the healthcare system of over 330 million patients. Drawing data from both providers and payers, the Healthcare Map is the only database of its kind to provide a longitudinal view of the entire patient journey: whether care was delivered in-network or out-of-network and through a specialist, an urgent care center, or a retail clinic. The data in this Fast Facts report represent the latest real–world patient data from October 2015 to December 2022.

How to cite this information: “Source: Komodo Health, Fast Facts: Lung Cancer, 2023”